F-star, John Haurum, CEO:Designing and developing bispecific antibody products to improve the treatment of cancer.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: F-star, John Haurum, CEO:Designing and developing bispecific antibody products to improve the treatment of cancer.
Released on: November 15, 2013. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this episode of PharmaTelevision News Review, filmed at BIO Europe 2013, Vienna, Paul Larsmon speaks to John Haurum, CEO of F-star.
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, filmed at BIO Europe 2013, Vienna, Paul Larsmon speaks to John Haurum, CEO of F-star. They discuss the formation of the new asset centric vehicle, F-star Alpha, an independent company which has been granted exclusive licenses to a range of oncology assets from F-star Biotechnology. F-star designs and develops bispecific antibody products to improve the treatment of cancer and is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Their Modular Antibody Technology™ offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products.
In this episode of PharmaTelevision News Review, filmed at BIO Europe 2013, Vienna, Paul Larsmon speaks to John Haurum, CEO of F-star. They discuss the formation of the new asset centric vehicle, F-star Alpha, an independent company which has been granted exclusive licenses to a range of oncology assets from F-star Biotechnology. F-star designs and develops bispecific antibody products to improve the treatment of cancer and is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Their Modular Antibody Technology™ offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products.
John Haurum
F-star
F-star